Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 19/20 | 0.53 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.53 |
| ▸ | CALCA | P06881 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795227 | 1.00 | CALCRL (0.53) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL4799683 | 0.92 | CALCRL (0.50) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL4799658 | 0.92 | CALCRL (0.50) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL3520941 | 0.92 | CALCA (0.56) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL3520944 | 0.92 | CALCA (0.56) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL13331928 | 0.90 | CALCRL (0.56) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL4799753 | 0.90 | CALCRL (0.60) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13331932 | 0.90 | CALCRL (0.64) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13331931 | 0.89 | CALCRL (0.54) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL13331922 | 0.89 | CALCRL (0.65) | CALCRLRAMP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439237-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20050282857-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 46/4885CALCA 3/4885 |
| US-20050282857-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 46/4885CALCA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.